Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer .
Filed returns
28
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | Health | Discussion on the EU Biotech Act, access to medicines, innovation, and Ireland's life sciences policy environment, including opportunities to strengthen research, development, manufacturing, and the competitiveness of… (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland’s National Life Sciences Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | EU Affairs | Ireland’s priorities for the 2026 Presidency of the Council of the European Union, including issues related to life sciences competitiveness, pharmaceutical manufacturing, and EU-level health emergency preparedness (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Taxation | Reform of R&D tax credit (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 7 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 6 | On lobbying.ie |
| May–Aug 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 14 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| May–Aug 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 5 | On lobbying.ie |
| May–Aug 2023 | Pfizer | Health | Ireland's reimbursement system and funding for new medicines (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Economic Development and Industry | Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Health | Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Energy and Natural Resources | Potential energy shortages (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 9 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 17 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Economic Development and Industry | Proposed COVID-19 Trips waiver (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Economic Development and Industry | Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 11 | 39.3% | |
| EU Affairs | 7 | 25.0% | |
| Economic Development and Industry | 5 | 17.9% | |
| Trade | 2 | 7.1% | |
| Budgetary matters | 1 | 3.6% | |
| Energy and Natural Resources | 1 | 3.6% | |
| Taxation | 1 | 3.6% |